Limestone Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.24M Sell
46,700
-69,700
-60% -$2.99M 0.17% 113
2026
Q1
$4.28M Buy
116,400
+49,000
+73% +$2.32M 0.34% 46
2025
Q4
$3.43M Buy
67,400
+64,800
+2,492% +$3.31M 0.33% 58
2025
Q3
$144K Sell
2,600
-5,800
-69% -$340K 0.01% 432
2025
Q2
$580K Buy
+8,400
New +$571K 0.05% 240

Other funds holding NVO

Limestone Investment Advisors's NVO Position: Q2 2026 in Review

Limestone Investment Advisors reduced its Novo Nordisk (NVO) stake by 48% in Q2 2026, selling an estimated $1.18M and leaving 29,130 shares worth $1.4M. The position accounts for 0.1% of the portfolio, ranked #167.

Limestone Investment Advisors first reported a position in NVO in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.1M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Limestone Investment Advisors held 29,130 shares of Novo Nordisk worth $1.4M as of Q2 2026.
  • Limestone Investment Advisors sold 27,380 Novo Nordisk shares in Q2 2026, an estimated $1.18M.
  • Novo Nordisk made up 0.1% of Limestone Investment Advisors's portfolio in Q2 2026, its #167 holding.
  • Limestone Investment Advisors first reported a position in Novo Nordisk in Q2 2025 and has held it in 5 quarters since.
  • Limestone Investment Advisors's Novo Nordisk position peaked at $2.1M in Q3 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Limestone Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.